The administration of polymerized human hemoglobin (Pyridoxylated) to a Jehovah's Witness after submyeloablative stem cell transplantation complicated by delayed graft failure.
A 55-yr-old woman with a history of B-cell lymphoma of the nasopharynx diagnosed in March 1999 eventually underwent submyeloablative allogeneic stem cell transplantation from a sibling donor in December 2002 after conventional treatment options were exhausted. The treatment approach was somewhat altered by the fact that the patient was a practicing Jehovah's Witness and refused blood-blood product transfusion. The course of her treatment was unremarkable until around day 100 posttransplant when she developed graft failure, leading to severe anemia. Blood transfusions were refused. Donor cells were re-infused. During this treatment period, the patient's hemoglobin dropped to a low of 2.7 g/dL, with the patient experiencing severe fatigue, dyspnea on exertion, headaches, and blurred vision. Polymerized human hemoglobin (pyridoxylated) (Poly- Heme, Northfield Laboratories Inc., Evanston, IL) was given under an emergency, compassionate use protocol and successfully bridged the patient's hemoglobin and relieved symptoms during her marrow recovery period.
Smith
Scott E
SE
Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL 60153, USA. ssmith8@lumc.edu
Toor
Amir
A
Rodriguez
Tulio
T
Stiff
Patrick
P
D001802:Blood Substitutes / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006454:Hemoglobins / Q000032:analysis / Q000627:therapeutic use*; D006801:Humans; D033221:Jehovah's Witnesses; D016393:Lymphoma, B-Cell / Q000628:therapy*; D008875:Middle Aged; D014184:Transplantation, Homologous
D001802:Blood Substitutes; D006454:Hemoglobins; C509893:PolyHeme